The use of low-dose rocuronium to facilitate laryngeal mask airway insertion.
In this two-phase study, the efficacy of low-dose rocuronium to facilitate laryngeal mask airway (LMA) insertion was evaluated. First, the onset time of 100, 150 and 300 micrograms.kg-1 rocuronium was determined using mechanomyography in three groups of patients (n = 10 in each) anaesthetized with propofol-fentanyl-nitrous oxide. In the second part, 100, 150 or 300 micrograms.kg-1 rocuronium or placebo was administered randomly to four groups of patients (n = 50 in each) in a double-blind manner. Following this, anaesthesia was induced with propofol 2.5 mg.kg-1. Patients in the group of 300 micrograms.kg-1 rocuronium or placebo received propofol after 1.5 min. Patients in the group of 100 or 150 micrograms.kg-1 rocuronium received propofol after 3 min. The LMA was inserted 90 sec later. Immediately before the induction of anaesthesia, patients were questioned about the symptoms of neuromuscular block. In phase 1, onset times were 180 sec (SD 41), 191 sec (59) and 89 sec (34), respectively. In phase 2, insertion of the LMA was graded as easy in 90.6% of patients receiving rocuronium, compared with 42% of patients who had only propofol (P < 0.05). Rocuronium improved the overall ease of LMA insertion. LMA insertion was graded easy in 80% of patients who received 100 micrograms.kg-1 rocuronium. The incidence of unpleasant effects was greatest with 300 micrograms.kg-1 rocuronium. The optimal dose needed to facilitate LMA insertion with minimal unpleasant effects appeared to be 100 micrograms.kg-1 rocuronium.
Naguib
M
M
MD University of Iowa College of Medicine, Department of Anesthesia, 200 Hawkins Drive, 6JCP Iowa City, Iowa 52242-1009, USA. mohamed-naguib@uiowa.edu
Samarkandi
A H
AH
D000328:Adult; D000732:Androstanols / Q000008:administration & dosage; D000769:Anesthesia, Inhalation; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017214:Laryngeal Masks; D008297:Male; D016343:Monitoring, Intraoperative; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage; D010147:Pain Measurement; D000077123:Rocuronium
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D000077123:Rocuronium